Pulse Biosciences offers a differentiated nsPFA cardiac ablation platform, but today’s valuation already prices in major clinical and commercial success despite pre-revenue cardiac risk.
Overview
Pulse Biosciences is a clinical-stage medtech company developing CellFX nanosecond pulsed field ablation technology for tissue-selective, nonthermal ablation. The company has shifted from dermatology and soft-tissue applications toward atrial fibrillation treatment through endocardial and surgical cardiac platforms. Q1 2026 marked first commercial revenue of $401,000 from Vybrance, but the investment case remains almost entirely tied to cardiac trial execution, PMA approvals, and eventual adoption. nsPFA’s potential advantages include reduced collateral damage, faster procedures, and lower neuromuscular stimulation versus thermal and microsecond PFA systems.